心臓　56/2　2024年2月号

出版社： 日本医学出版
発行日： 2024-02-15
分野： 臨床医学：内科  >  雑誌
ISSN： 05864488
雑誌名：
電子書籍版： 2024-02-15
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

目次

  • Open HEART
    心臓リハビリテーションの普及を願って

    HEART’s Selection
    進化し続ける経皮的大動脈弁置換術（TAVI）治療の現状
    1.本邦におけるTAVIの現状と今後の展望
    2.透析患者へのTAVIの現状と成績
    3.TAV in SAV, TAV in TAV とライフタイムマネジメント
    4.TAVI弁の種類と使い分け
    5.増えてきたTAVI患者とTAVI後の患者がACSになったら
    6.TAVI治療後の至適抗血栓療法

    [連載]HEART’s Up To Date
    循環器医が知っておくべき最新のエビデンス

    HEART’s Original
    [臨床研究]
    HMG-CoA還元酵素阻害薬の院内採用規格変更が医師の処方行動変容につながるかの検討

    [総説]
    心臓血管外科領域における漢方薬　－処方の現状と今後の展望－

    [Editorial Comment]
    古川論文に対するEditorial　Comment

    [症例]
    ヘパリン起因性血小板減少症(HIT）を合併した心拍動下冠動脈バイパス術の1例

    [Editorial Comment]
    藤井論文に対するEditorial　Comment

    [症例]
    器質的高度冠動脈狭窄を伴う冠攣縮性狭心症症例に対し冠動脈バイパス術を施行した１例

    [症例]
    敗血症から乳頭筋完全断裂のみを起こした感染性心内膜炎の１治験例

    研究会
    第56回　河口湖心臓討論会

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【HEART' s Selection】

P.91 掲載の参考文献
1) Cribier A, Eltchaninoff H, Bash A, et al : Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis : first human case description. Circulation 2002 ; 106 : 3006-3008
 
2) Leon MB, Smith CR, Mack MJ, et al : Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2016 ; 374 : 1609-1620
 
3) Sondergaard L, Steinbruchel DA, Ihlemann N, et al : Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement : The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial. Circ Cardiovasc Interv 2016 ; 9 : e003665
PubMed
4) Baumgartner H, Falk V, Bax JJ, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017 ; 38 : 2739-2791
 
5) Nishimura RA, Otto CM, Bonow RO, et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017 ; 135 : e1159-e1195
 
6) Popma JJ, Deeb GM, Yakubov SJ, et al : Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med 2019 ; 380 : 1706-1715
 
7) Mack MJ, Leon MB, Thourani VH, et al : Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019 ; 380 : 1695-1705
 
8) Izumi C, Eishi K, Ashihara K, et al : JCS/JSCS/JATS/JSVS 2020 Guidelines on the Management of Valvular Heart Disease. Circ J 2020 ; 84 : 2037-2119
 
9) Otto CM, Nishimura RA, Bonow RO, et al : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021 ; 143 : e72-e227
 
10) Vahanian A, Beyersdorf F, Praz F, et al : 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022 ; 43 : 561-632
 
11) Jorgensen TH, Thyregod HGH, Ihlemann N, et al : Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J 2021 ; 42 : 2912-2919
 
12) Sathananthan J, Lauck S, Polderman J, et al : Ten year follow-up of high-risk patients treated during the early experience with transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2021 ; 97 : E431-E437
 
13) Dewey TM, Brown DL, Das TS, et al : High-risk patients referred for transcatheter aortic valve implantation : management and outcomes. Ann Thorac Surg 2008 ; 86 : 1450-1456 ; discussion 1456-1457
 
14) Piazza N, van Gameren M, Juni P, et al : A comparison of patient characteristics and 30-day mortality outcomes after transcatheter aortic valve implantation and surgical aortic valve replacement for the treatment of aortic stenosis : a two-centre study. EuroIntervention 2009 ; 5 : 580-588
 
15) Hayashida K, Lefevre T : Treatment and prevention of aortic regurgitation after transcatheter aortic valve implantation. EuroIntervention 2012 ; 8 Suppl Q : Q34-40
 
16) Binder RK, Rodes-Cabau J, Wood DA, et al : Transcatheter aortic valve replacement with the SAPIEN 3 : a new balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv 2013 ; 6 : 293-300
 
17) Thourani VH, Kodali S, Makkar RR, et al : Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients : a propensity score analysis. Lancet 2016 ; 387 : 2218-2225
 
18) Forrest JK, Mangi AA, Popma JJ, et al : Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. JACC Cardiovasc Interv 2018 ; 11 : 160-168
 
19) Manoharan G, Spence MS, Rodes-Cabau J, Webb JG : St Jude Medical Portico valve. EuroIntervention 2012 ; 8 Suppl Q : Q97-101
 
20) Eckel CE, Kim WK, Grothusen C, et al : Comparison of the New-Generation Self-Expanding NAVITOR Transcatheter Heart Valve with Its Predecessor, the PORTICO, in Severe Native Aortic Valve Stenosis. J Clin Med 2023 ; 12 : 3999
PubMed
21) Rheude T, Pellegrini C, Lutz J, et al : Transcatheter Aortic Valve Replacement With Balloon-Expandable Valves : Comparison of SAPIEN 3 Ultra Versus SAPIEN 3. JACC Cardiovasc Interv 2020 ; 13 : 2631-2638
 
22) Nazif TM, Cahill TJ, Daniels D, et al : Real-World Experience With the SAPIEN 3 Ultra Transcatheter Heart Valve : A Propensity-Matched Analysis From the United States. Circ Cardiovasc Interv 2021 ; 14 : e010543
PubMed
23) Bavaria JE, Griffith B, Heimansohn DA, et al : Five-year Outcomes of the COMMENCE Trial Investigating Aortic Valve Replacement With RESILIA Tissue. Ann Thorac Surg 2023 ; 115 : 1429-1436
 
24) Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, et al : Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg 2015 ; 99 : 831-837
 
25) Spaziano M, Mylotte D, Theriault-Lauzier P, et al : Transcatheter aortic valve implantation versus redo surgery for failing surgical aortic bioprostheses : a multicentre propensity score analysis. EuroIntervention 2017 ; 13 : 1149-1156
 
26) Nalluri N, Atti V, Munir AB, et al : Valve in valve transcatheter aortic valve implantation (ViV-TAVI) versus redo-Surgical aortic valve replacement (redo-SAVR) : A systematic review and meta-analysis. J Interv Cardiol 2018 ; 31 : 661-671
 
27) Silaschi M, Wendler O, Seiffert M, et al : Transcatheter valve-in-valve implantation versus redo surgical aortic valve replacement in patients with failed aortic bioprostheses. Interact Cardiovasc Thorac Surg 2017 ; 24 : 63-70
 
28) Bapat VN, Zaid S, Fukuhara S, et al : Surgical Explantation After TAVR Failure : Mid-Term Outcomes From the EXPLANT-TAVR International Registry. JACC Cardiovasc Interv 2021 ; 14 : 1978-1991
 
29) Landes U, Sathananthan J, Witberg G, et al : Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses. J Am Coll Cardiol 2021 ; 77 : 1-14
PubMed
30) Marwick TH, Amann K, Bangalore S, et al : Chronic kidney disease and valvular heart disease : conclusions from a Kidney Disease : Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019 ; 96 : 836-849
 
31) Ohara T, Hashimoto Y, Matsumura A, et al : Accelerated progression and morbidity in patients with aortic stenosis on chronic dialysis. Circ J 2005 ; 69 : 1535-1539
 
32) Yamauchi T, Yamamoto H, Miyata H, et al : Surgical Aortic Valve Replacement for Aortic Stenosis in Dialysis Patients - Analysis of Japan Cardiovascular Surgery Database. Circ J 2020 ; 84 : 1271-1276
 
33) Maeda K, Kuratani T, Torikai K, et al : Early Outcomes in Japanese Dialysis Patients Treated With Transcatheter Aortic Valve Implantation. Circ J 2015 ; 79 : 2713-2719
 
34) Maeda K, Kuratani T, Mizote I, et al : One-year outcomes of the pivotal clinical trial of a balloon-expandable transcatheter aortic valve implantation in Japanese dialysis patients. J Cardiol 2021 ; 78 : 533-541
 
35) Mentias A, Desai MY, Saad M, et al : Management of Aortic Stenosis in Patients With End-Stage Renal Disease on Hemodialysis. Circ Cardiovasc Interv 2020 ; 13 : e009252
PubMed
36) Kaneko T, Vemulapalli S, Kohsaka S, et al : Practice Patterns and Outcomes of Transcatheter Aortic Valve Replacement in the United States and Japan : A Report From Joint Data Harmonization Initiative of STS/ACC TVT and J-TVT. J Am Heart Assoc 2022 ; 11 : e023848
 
37) Sawaya FJ, Bajoras V, Vanhaverbeke M, et al : Intravascular Lithotripsy-Assisted Transfemoral TAVI : The Copenhagen Experience and Literature Review. Front Cardiovasc Med 2021 ; 8 : 739750
PubMed
38) Quagliana A, Montarello NJ, Vanhaverbeke M, et al : Orbital atherectomy to facilitate transfemoral transcatheter aortic valve implantation in patients with calcified iliofemoral arteries : a case series. Eur Heart J Case Rep 2023 ; 7 : ytad310
PubMed
39) Strange G, Stewart S, Celermajer D, et al : Poor Long-Term Survival in Patients With Moderate Aortic Stenosis. J Am Coll Cardiol 2019 ; 74 : 1851-1863
 
40) Mentias A, Saad M, Menon V, et al : Transcatheter vs Surgical Aortic Valve Replacement in Pure Native Aortic Regurgitation. Ann Thorac Surg 2023 ; 115 : 870-876
 
41) Sanchez-Luna JP, Martin P, Dager AE, et al : Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation. EuroIntervention 2023 ; 19 : 580-588
 
42) Adam M, Tamm AR, Wienemann H, et al : Transcatheter Aortic Valve Replacement for Isolated Aortic Regurgitation Using a New Self-Expanding TAVR System. JACC Cardiovasc Interv 2023 ; 16 : 1965-1973
 
43) Messas E, Ijsselmuiden A, Trifunovic-Zamaklar D, et al : Treatment of severe symptomatic aortic valve stenosis using non-invasive ultrasound therapy : a cohort study. Lancet 2023 ; 402 : 2317-2325
 
P.97 掲載の参考文献
1) Schiffrin EL, Lipman ML, Mann JF : Chronic kidney disease : effects on the cardiovascular system. Circulation 2007 ; 116 : 85-97
 
2) Perkovic V, Hunt D, Griffin SV, et al : Accelerated progression of calcific aortic stenosis in dialysis patients. Nephron Clin Pract 2003 ; 94 : c40-45
 
3) Ohara T, Hashimoto Y, Matsumura A, et al : Accelerated progression and morbidity in patients with aortic stenosis on chronic dialysis. Circ J 2005 ; 69 : 1535-1539
 
4) 新田孝作, 政金生人, 花房規男, ほか : わが国の慢性透析療法の現況 (2018年12月31日現在). 透析会誌 2019 ; 52 : 679-754
 
5) Yamauchi T, Yamamoto H, Miyata H, et al : Surgical aortic valve replacement for aortic stenosis in dialysis patients-analysis of japan cardiovascular surgery database. Circ J 2020 ; 84 : 1271-1276
 
6) Kawase Y, Taniguchi T, Morimoto T, et al : Severe aortic stenosis in dialysis patients. J Am Heart Assoc 2017 ; 6 : e004961
PubMed
7) Smith CR, Leon MB, Mack MJ, et al : Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011 ; 364 : 2187-2198
 
8) Adams DH, Popma JJ, Reardon MJ, et al : Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014 ; 370 : 1790-1798
 
9) Leon MB, Smith CR, Mack MJ, et al : Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016 ; 374 : 1609-1620
 
10) Reardon MJ, Van Mieghem NM, Popma JJ, et al : Surgical or Transcather Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2017 ; 376 : 1321-1331
 
11) Mack MJ, Leon MB, Thourani VH, et al : Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019 ; 380 : 1695-1705
 
12) Popma JJ, Deeb GM, Yakubov SJ, et al : Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019 ; 380 : 1706-1715
 
13) Mentias A, Desai MY, Saad M, et al : Management of aortic stenosis in patients with end-stage renal disease on hemodialysis. Circ Cardiovasc Interv 2020 ; 13 : e009252
PubMed
14) Maeda K, Kuratani T, Torikai K, et al : Early outcomes in Japanese dialysis patients treated with transcatheter aortic valve implantation. Circ J 2015 ; 79 : 2713-2719
 
15) Maeda K, Kuratani T, Mizote I, et al : One-year outcomes of the pivotal clinical trial of a balloon-expandable transcatheter aortic valve implantation in Japanese dialysis patients. J Cardiol 2021 ; 78 : 533-541
 
16) Inohara T, Yamamoto M, Watanabe Y, et al : TAVI for dialysis patients ; Insight from the OCEAN-TAVI Dialysis cohort. JCS meeting 2023, Fukuoka, 2023/3
 
17) Maeda K, Kuratani T, Mizote I, et al : Midterm outcomes of transcatheter aortic valve replacement in dialysis patients with aortic valve stenosis. Circ J 2019 ; 83 : 1600-1606
 
18) Okada N, Tajima K, Takami Y, et al : Valve selection for the aortic position in dialysis patients. Ann Thorac Surg 2015 ; 99 : 1524-1531
 
P.103 掲載の参考文献
1) Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, et al : Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg 2015 ; 99 (3) : 831-837
 
2) Jorgensen TH, et al : NOTION-The Nordic Aortic Valve Intervention Trial. Late-breaking science on valve disease and hypertrophic cardiomyopathy. ESC Congress 2023. Aug 28 2023 ; Amsterdam, Nederland
 
3) Midha PA, Raghav V, Sharma R, et al : The Fluid Mechanics of Transcatheter Heart Valve Leaflet Thrombosis in the Neosinus. Circulation 2017 ; 136 (17) : 1598-1609
 
4) Tarantini G, Dvir D, Tang GHL : Transcatheter aortic valve implantation in degenerated surgical aortic valves. EuroIntervention 2021 ; 17 (9) : 709-719
 
P.107 掲載の参考文献
1) Smith CR, Leon MB, Mack MJ, et al : Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011 ; 364 : 2187-2198
 
2) Leon MB, Smith CR, Mack M, et al : Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010 ; 363 : 1597-1607
 
3) Leon MB, Smith CR, Mack MJ, et al : Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2016 ; 374 : 1609-1620
 
4) Mack MJ, Leon MB, Thourani VH, et al : Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019 ; 380 : 1695-1705
 
5) Popma JJ, Deeb GM, Yakubov SJ, et al : Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med 2019 ; 380 : 1706-1715
 
6) Barbanti M, Yang TH, Rodes Cabau J, et al : Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement. Circulation 2013 ; 128 : 244-253
 
7) Linke A, Wenaweser P, Gerckens U, et al : Treatment of aortic stenosis with a self-expanding transcatheter valve : the International Multi-centre ADVANCE Study. Eur Heart J 2014 ; 35 : 2672-2684
 
8) Siontis GC, Juni P, Pilgrim T, et al : Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR : a meta-analysis. J Am Coll Cardiol 2014 ; 64 : 129-140
 
9) Watanabe Y, Chevalier B, Hayashida K, et al : Comparison of multislice computed tomography findings between bicuspid and tricuspid aortic valves before and after transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2015 ; 86 : 323-330
 
10) Jorgensen TH, Thyregod HGH, Ihlemann N, et al : Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J 2021 ; 42 : 2912-2919
 
11) Mack MJ, Leon MB, Thourani VH, et al ; PARTNER 3 Investigators : Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years. N Engl J Med 2023 ; 389 : 1949-1960
 
P.114 掲載の参考文献
1) Goel SS, Ige M, Tuzcu EM, et al : Severe aortic stenosis and coronary artery disease--implications for management in the transcatheter aortic valve replacement era : a comprehensive review. J Am Coll Cardiol 2013 ; 62 : 1-10
 
2) Mentias A, Desai MY, Saad M, et al : Incidence and Outcomes of Acute Coronary Syndrome After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv 2020 ; 13 : 938-950
 
3) Barbanti M, Costa G, Picci A, et al : Coronary Cannulation After Transcatheter Aortic Valve Replacement : The RE-ACCESS Study. JACC Cardiovasc Interv 2020 ; 13 : 2542-2555
 
4) Azumi Y, Nakama T, Obunai K, Watanabe H : A case of challenging percutaneous coronary intervention following surgical aortic valve replacement with a sutureless aortic bioprosthesis. J Cardiol Cases 2020 ; 22 : 198-201
 
5) Hirose S, Enta Y, Ishii K, et al : En face view of the transcatheter heart valve from deep right-anterioroblique cranial position for coronary access after transcatheter aortic valve implantation : a case series. Eur Heart Case Rep 2022 ; 6 : ytac059
PubMed
6) Tanaka T, Okamura A, Iwakura K, et al : Efficacy and Feasibility of the 3-Dimensional Wiring Technique for Chronic Total Occlusion Percutaneous Coronary Intervention : First Report of Outcomes of the 3-Dimensional Wiring Technique. JACC Cardiovasc Interv 2019 ; 12 : 545-555
 
7) Miura I, Horisawa S, Kawamata T, Taira T : Biplane fluoroscopy-guided percutaneous spinal cord stimulation. Neurochirurgie 2023 ; 69 : 101467
PubMed
8) Sotir A, Klopf J, Wolf F, et al : Monoplane versus biplane fluoroscopy in patients undergoing fenestrated/branched endovascular aortic repair. J Vasc Surg 2023 ; 77 : 1359-1366.e2
 
9) Nakashima M, Miyasaka M, Satomi N, et al : Implications of the En Face View of Transcatheter Heart Valves for Coronary Access Post-TAVR. JACC Cardiovasc Interv 2023 : 16 : 3049-3051
 
10) Ochiai T, Chakravarty T, Yoon SH, et al : Coronary Access After TAVR. JACC Cardiovasc Interv 2020 ; 13 : 693-705
 
11) Hirose S, Miyasaka M, Tada N : Utilizing the en face view for unfavorable coronary access after transcatheter aortic valve replacement. Cardiovasc Interv Ther 2023 ; 38 : 256-257
 
12) Yudi MB, Sharma SK, Tang GHL, Kini A : Coronary Angiography and Percutaneous Coronary Intervention After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2018 ; 71 : 1360-1378
 
P.120 掲載の参考文献
1) Yamamoto M, Otsuka T, Shimura T, et al : Incidence, Timing, and Causes of Late Bleeding After TAVR in an Asian Cohort. JACC Asia 2022 ; 2 (5) : 622-632
 
2) Otto CM, Nishimura RA, Bonow RO, et al : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021 ; 143 (5) : e72-e227
 
3) Izumi C, Eishi K, Ashihara K, et al ; Japanese Circulation Society Joint Working Group : JCS/JSCS/JATS/JSVS 2020 Guidelines on the Management of Valvular Heart Disease. Circ J 2020 ; 84 (11) : 2037-2119
 
4) Vahanian A, Beyersdorf F, Praz F, et al ; ESC/EACTS Scientific Document Group : 2021 ESC/EACTS Guidelines for the management of valvular heart disease : Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio Thoracic Surgery (EACTS). Eur Heart J 2022 ; 43 (7) : 5 61-632
 
5) Rodes Cabau J, Masson JB, Welsh RC, et al : Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve : The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. JACC Cardiovasc Interv 2017 ; 10 (13) : 1357-1365
 
6) Brouwer J, Nijenhuis VJ, Delewi R, et al : Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 2020 ; 383 (15) : 1447-1457
PubMed
7) Dangas GD, Tijssen JGP, Wohrle J, et al : A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020 ; 382 (2) : 120-129
 
8) Kobari Y, Inohara T, Saito T, et al : Aspirin Versus Clopidogrel as Single Antithrombotic Therapy After Transcatheter Aortic Valve Replacement : Insight From the OCEAN-TAVI Registry. Circ Cardiovasc Interv 2021 ; 14 (5) : e010097
PubMed
9) Kobari Y, Inohara T, Tsuruta H, et al : No Antithrombotic Therapy After Transcatheter Aortic Valve Replacement : Insight From the OCEAN-TAVI Registry. JACC Cardiovasc Interv 2023 ; 16 (1) : 79-91
 
10) Inohara T, Otsuka T, Watanabe Y, et al : Rationale and design of Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation (NAPT) Trial. Contemp Clin Trials 2023 ; 134 : 107358
PubMed
11) Kawashima H, Watanabe Y, Hioki H, et al : Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR. JACC Cardiovasc Interv 2020 ; 13 (22) : 2587-2597
 
12) Hioki H, Watanabe Y, Kozuma K, et al : Timing of Susceptibility to Mortality and Heart Failure in Patients With Preexisting Atrial Fibrillation After Transcatheter Aortic Valve Implantation. Am J Cardiol 2017 ; 120 (9) : 1618-1625
 
13) Mizutani K, Nakazawa G, Yamaguchi T, et al : Academic Research Consortium High Bleeding Risk Criteria associated with 2-year bleeding events and mortality after transcatheter aortic valve replacement discharge : a Japanese Multicentre Prospective OCEAN-TAVI Registry Study. Eur Heart J Open 2021 ; 1 (3) : oeab036
 
14) Nijenhuis VJ, Brouwer J, Delewi R, et al : A nticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 2020 ; 382 (18) : 1696-1707
 
15) Van Mieghem NM, Unverdorben M, Hengstenberg C, et al : Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med 2021 ; 385 (23) : 2150-2160
 
16) Granger CB, Alexander JH, McMurray JJ, et al : Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 ; 365 (11) : 981-992
 
17) Watanabe Y, Hayashida K, Yamamoto M, et al : Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients-A Subanalysis of the ENVISAGE-TAVI AF Trial. Circ J 2022 ; 86 (11) : 1756-1763
 
18) Collet JP, Van Belle E, Thiele H, et al : Apixaban vs. standard of care after transcatheter aortic valve implantation : the ATLANTIS trial. Eur Heart J 2022 ; 43 (29) : 2783-2797
 
19) Aggarwal R, Ruff CT, Virdone S, et al : Development and Validation of the DOAC Score : A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. Circulation 2023 ; 148 (12) : 936-946
 
20) Kapadia SR, Krishnaswamy A, Whisenant B, et al : Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients with Atrial Fibrillation. Circulation 2023 Oct 24. doi : 10.1161/CIRCULATIONAHA.123.067312. [Online ahead of print]
 
21) Asami M, Naganuma T, Ohno Y, et al : Initial Japanese Multicenter Experience and Age-Related Outcomes Following Left Atrial Appendage Closure : The OCEAN-LAAC Registry. JACC Asia 2023 ; 3 (2) : 272-284
 

【HEART' s Original】

P.133 掲載の参考文献
1) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン 2022年版. https://www.j-athero.org/jp/jas_gl2022/ (cited 2023 May 30)
 
2) Grundy SM, Stone NJ, Bailey AL, et al : 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019 ; 139 : e1082-e1143
 
3) Mach F, Baigent C, Catapano AL, et al : 2019 ESC/EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk. Eur Heart J 2020 ; 41 : 111-188
 
4) Sawano M, Kohsaka S, Abe T, et al : Patterns of statin non-prescription in patients with established coronary artery disease : A report from a contemporary multicenter Japanese PCI registry. PLoS ONE 2017 ; 12 : e0182687
PubMed
5) Nanna MG, Navar AM, Wang TY, et al : Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States : Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J 2019 ; 214 : 113-124
 
6) Saku K, Zhang B, Noda K ; PATROL Trial Investigators : Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL) : the PATROL trial. Circ J 2011 ; 75 : 1493-1505
 
7) FINDAT : HMG-CoA還元酵素阻害剤 (スタチン系薬) 薬効群比較レビュー 第3版 2022年11月17日作成. https://www.findat.jp (cited 2023 May 30)
 
8) Taguchi I, Iimuro S, Iwata H, et al : High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD) : A Randomized Superiority Trial. Circulation 2018 ; 137 : 1997-2009
 
9) Natsuaki M, Furukawa Y, Morimoto T, et al : Intensity of Statin Therapy, Achieved Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Outcomes in Japanese Patients After Coronary Revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. Circ J 2012 ; 76 : 1369-1379
 
10) LaRosa JC, Grundy SM, Waters DD, et al : Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med 2005 ; 352 : 1425-1435
 
11) Barter PJ, Yamashita S, Laufs U, et al : Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines : insights from a web-based physician survey. Lipids Health Dis 2020 ; 19 : 131
 
12) Yamashita S, Masuda D, Arai H, Matsuzawa Y : Cultural Barriers in the Treatment of Dyslipidemia : A Survey of Japanese Physician Attitudes. J Atheroscler Thromb 2019 ; 26 : 154-169
 
13) Patel MS, Kurtzman GW, Kannan S, et al : Effect of an Automated Patient Dashboard Using Active Choice and Peer Comparison Performance Feedback to Physicians on Statin Prescribing : The PRESCRIBE Cluster Randomized Clinical Trial. JAMA Netw Open 2018 ; 1 : e180818
PubMed
14) Adusumalli S, Kanter GP, Small DS, et al : Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing : A Cluster Randomized Clinical Trial. JAMA Cardiol 2023 ; 8 : 23-30
PubMed
15) Rashid S, Suero-Abreu GA, Tysarowski M, et al : Increasing statin prescription rates to prevent cardiovascular disease among high-risk populations : a quality improvement intervention centred on a novel interactive tool. BMJ Open Qual 2022 ; 11 : e001947
PubMed
16) Alameddine R, Seifeddine S, Ishak H, Antoun J : Improving statin prescription through the involvement of nurses in the provision of ASCVD score : a quality improvement initiative in primary care. Postgrad Med 2020 ; 132 : 479-484
 
17) Naugler C, Cook C, Morrin L, et al : Statin Prescriptions for High-Risk Patients Are Increased by Laboratory-Initiated Framingham Risk Scores : A Quality-Improvement Initiative. Can J Cardiol 2017 ; 33 : 682-684
 
18) Drake ES, Harris DK, Marciniak MW : Community pharmacist-led intervention to identify persons with diabetes not on statin therapy. J Am Pharm Assoc (2003) 2018 ; 58 : S125-S130
PubMed
19) Renner HM, Hollar A, Stolpe SF, Marciniak MW : Pharmacist-to-prescriber intervention to close therapeutic gaps for statin use in patients with diabetes : A randomized controlled trial. J Am Pharm Assoc (2003) 2017 ; 57 : S236-S242
 
20) 増原慶壮 : ファーマシューティカルケアに基づいた病棟薬剤業務の実践. 医療 2015 ; 69 : 520-524
 
21) Patel MS, Volpp KG, Asch DA : Nudge Units to Improve the Delivery of Health Care. N Engl J Med 2018 ; 378 : 214-216
 
22) Martin SJ, Bassi S, Dunbar-Rees R : Commitments, norms and custard creams-a social influence approach to reducing did not attends (DNAs). J R Soc Med 2012 ; 105 : 101-104
PubMed
23) Manz CR, Parikh RB, Small DS, et al : Effect of Integrating Machine Learning Mortality Estimates With Behavioral Nudges to Clinicians on Serious Illness Conversations Among Patients With Cancer : A Stepped-Wedge Cluster Randomized Clinical Trial. JAMA Oncol 2020 ; 6 : e204759
 
24) DeVore AD, Granger BB, Fonarow GC, et al : Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction : The CONNECT-HF Randomized Clinical Trial. JAMA 2021 ; 326 : 314-323
 
P.141 掲載の参考文献
1) Ang-Lee MK, Moss J, Yuan CS : Herbal medicines and perioperative care. JAMA 2001 ; 286 : 208-216
 
2) Hodges PJ, Kam PCA : The peri-operative implications of herbal medicines. Anaesthesia 2002 ; 57 : 889-899
 
3) Levy I, Attias S, Ben-Arye E, et al : Perioperative risks of dietary and herbal supplements. World J Surg 2017 ; 41 : 927-934
 
4) Okura Y, Ramadan MM, Ohno Y, et al : Impending epidemic-Future projection of heart failure in Japan to the year 2055. Circ J 2008 ; 72 : 489-491
 
5) Tachjian A, Maria V, Jahangir A : Use of herbal products and potential interactions in patients with cardiovascular disease. J Am Coll Cardiol 2010 ; 55 : 515-525
 
6) Hao P, Jiang F, Cheng J, et al : Traditional Chinese Medicine for Cardiovascular Disease : Evidence and Potential Mechanisms. J Am Coll Cardiol 2017 ; 69 : 2952-2966
 
7) Wang Y, Wang Q, Li C, et al : A review of Chinese herbal medicine for the treatment of chronic heart failure. Curr Pharm Des 2017 ; 23 : 5115-5124
 
8) Shibata C, Sasaki I, Naito H, et al : The herbal medicine Dai-kenchu-Tou stimulates upper gut motility through cholinergic and 5-hydroxytryptamine 3 receptors in conscious dogs. Surgery 1999 ; 126 : 918-924
 
9) Kono T, Kanematsu T, Kitajima M : Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines : is it time yet? Surgery 2009 ; 146 : 837-840
 
10) 菅隼人, 内田英二, 松本智司, ほか : 大建中湯の腸管運動に対する効果. 日外科系連会誌 2012 ; 37 : 719-723
 
11) 壁島康郎, 高橋洋子, 亀山哲章, ほか : 大腸癌手術症例における大建中湯を用いた術後リハビリテーションの検討. 日消外会誌 2005 ; 38 : 592-597
 
12) Yoshikawa K, Shimada M, Nishioka M, et al : The effects of the Kampo medincine (Japanese herbal medicine) "Daikenchuto" on the surgical inflammatory response following laparoscopic colorectal resection. Surg Today 2012 ; 42 : 646-651
 
13) Nishino T, Yoshida T, Goto M, et al : The effects of the herbal medicine Daikenchuto (TJ-100) after esophageal cancer resection, open-label, randomized controlled trial. Esophagus 2018 ; 15 : 75-82
 
14) Mangi AA, Christinson-Lagay ER, Torchiana DF, et al : Gastrointestinal complications in patients undergoing heart operation. An analysis of 8,709 consecutive cardiac surgical patients. Ann Surg 2005 ; 241 : 895-901
 
15) Lorusso R, Mariscalco G, Vizzardi E, et al : Acute bowel ischemia after heart operations. Ann Thorac Surg 2014 ; 97 : 2219-2227
 
16) 高垣有作, 川崎貞男, 駒井宏好, ほか : 腹部大動脈瘤術後腸管麻痺における大建中湯の腸管蠕動改善効果. 日臨外会誌 2000 ; 61 : 325-328
 
17) Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al : A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005 ; 66 : 248-252
 
18) Terawaki K, Ikarashi Y, Sekiguchi K, et al : Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells. J Ethnopharmacol 2010 ; 127 : 306-312
 
19) Kawakami Z, Kanno H, Ueki T, et al : Neuroprotective effects of yokukansan, a traditional Japanese medicine, on glutamate-mediated excitotoxicity in cultured cells. Neuroscience 2009 ; 159 : 1397-1407
 
20) Smulter N, Lingehall HC, Gustafson Y, et al : Delirium after cardiac surgery : incidence and risk factors. Interact Cardiovasc Thorac Surg 2013 ; 17 : 790-796
 
21) Chen H, Mo L, Hu H, et al : Risk factors of postoperative delirium after cardiac surgery : a meta-analysis. J Cardiothorac Surg 2021 ; 16 : 113. https://doi.org/10.1186/s13019-021-01496-w
 
22) Galyfos GC, Geropapas GE, Sianou A, et al : Risk factors for postoperative delirium in patients undergoing vascular surgery. J Vasc Surg 2017 ; 66 : 937-946
 
23) 高瀬信弥 : 抑肝散の最新研究 高齢者の心臓大血管術後に起こるせん妄に対する抑肝散の効果. 漢方医 2010 ; 34 : 132-134
 
24) 高瀬信弥, 横山斉 : 術後せん妄-抑肝散-心臓大血管術後せん妄の予防効果. 臨床外科 2013 ; 68 : 1314-1318
 
25) 永渕弘之, 熊坂治, 麻生俊英 : 小児心臓手術後におけるデクスメデトミジンと抑肝散併用療法の鎮静効果. 日集中医誌 2017 ; 24 : 345-347
 
26) Takeda H, Sadakane C, Hattori T, et al : Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 2008 ; 134 : 2004-2013
 
27) Lopez-Delgado JC, Munoz-Del Rio G, Flordelis-Lasierra JL, Putzu A : Nutrition in adult cardiac surgery : Preoperative evaluation, management in the postoperative period, and clinical implications for outcomes. J Cardiothorac Vasc Anesth 2019 ; 33 : 3143-3162
 
28) Takiguchi S, Hiura Y, Takahashi T, et al : Effect of rikkunshito, a Japanese herbal medicine, on gastrointestinal symptoms and ghrelin levels in gastric cancer patients after gastrectomy. Gastric Cancer 2013 ; 16 : 167-174
 
29) Gunji S, Ueda S, Yoshida M, et al : Effects of rikkunshito, a kampo medicine, on quality of life after proximal gastrectomy. J Surg Res 2013 ; 185 : 575-580
 
30) 神應知道, 韓晶岩, 相馬一亥 : 集中治療後の食欲低下患者に対して東洋医学的アプローチを行った3症例. 日集中医誌 2009 ; 16 : 211-212
 
31) 渡辺賢治 : 集中治療患者の食欲不振に対する漢方治療の有用性. 日集中医誌 2009 ; 16 : 148-150
 
32) Hayakawa T, Arakawa T, Kase Y, et al : Liu-Jun-Zi-Tang, a kampo medicine, promotes adaptive relaxation in isolated guinea pig stomachs. Drug Exp Clin Res 1999 ; 25 : 211-218
 
33) Ahn YM, Cho KW, Kang DG, Lee HS : Oryeongsan (Wulingsan), a traditional Chinese herbal medicine, induces natriuresis and diuresis along with an inhibition of the renin-angiotensin-aldosterone system in rats. J Ethnopharmacol 2012 ; 141 : 780-785
 
34) 磯濱洋一郎 : 炎症・水毒-和漢薬によるアクアポリン水チャネルの機能調節. 漢方と最新治療 2008 ; 17 : 27-35
 
35) 川原隆道, 千葉浩輝, 高橋浩子, ほか : 慢性腎臓病合併慢性心不全患者における五苓散の有用性と安全性の臨床的検討. 日東洋医会誌 2019 ; 70 : 57-64
 
36) 玉野雅裕, 加藤士郎, 岡村麻子, ほか : 難治性高齢者心不全に対して五苓散追加投与が有効であった2症例. 日東洋医会誌 2018 ; 69 : 275-280
 
37) 林忍, 渋谷慎太郎, 大久保博世, ほか : 下肢静脈瘤に伴う浮腫に対する五苓散の治療効果. 日血外会誌 2014 ; 23 : 831-835
 
38) Komiyama S, Takeya C, Takahashi R, et al : Feasibility study on the effectiveness of Goreisan-based Kampo therapy for lower abdominal lymphedema after retroperitoneal lymphadenectomy via extraperitoneal approach. J Obstet Gynaecol Res 2015 ; 41 : 1449-1456
 
39) 有地滋, 久保直徳 : 芍薬甘草湯の医薬学的研究および臨床効果について. 基礎と臨床 1977 ; 11 : 3121-3131
 
40) Chou CT, Wasserstein A, Schumacher HR Jr, Fernandez P : Musculoskeletal manifestations in hemodialysis patients. J Rheumatol 1985 ; 12 : 1149-1153
 
41) 室賀一宏, 松井則明 : 透析患者の下肢の筋痙攣に対する芍薬甘草湯の使用経験. 日東洋医会誌 1995 ; 46 : 467-469
 
42) Hyodo T, Taira T, Takemura T, et al : Immediate effect of Shakuyaku-kanzo-to on muscle cramp in hemodialysis patients. Nephron Clin Pract 2006 ; 104 : C28-32
 
43) 大谷真二, 清水康廣, 杉山悟, 宮出喜生 : 下肢静脈瘤の有痛性筋痙攣に対する芍薬甘草湯の効果. 漢方医 2005 ; 29 : 221-223
 
44) Iwasaki K, Kato S, Monma Y, et al : A pilot study of banxia houpu tang, a traditional Chinese medicine, for reducing pneumonia risk in older adults with dementia. J Am Geriatr Soc 2007 ; 55 : 2035-2040
 
45) Kaneko A, Cho S, Hirai K, et al : Hange-koboku-to, a Kampo medicine, modulates cerebral levels of 5-HT (5-hydroxytryptamine), NA (noradrenaline) and DA (dopamine) in mice. Phytother Res 2005 ; 19 : 491-495
 
46) Kawago K, Nishibe T, Shindo S, et al : A double-blind randomized controlled trial to determine the preventive effect of Hangekobokuto on aspiration pneumonia in patients undergoing cardiovascular surgery. Ann Thorac Cardiovasc Surg 2019 ; 25 : 318-325
 
47) Huang W, Zhang J, Moore DD : A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest 2004 ; 113 : 137-143
 
48) Kaiho T, Tsuchiya S, Yanagisawa S, et al : Effect of the herbal medicine Inchin-Ko-To for serum bilirubin in hepatectomized patients. Hepatogastroenterology 2008 ; 55 : 150-154
 
49) Sharma P, Ananthanarayanan C, Vaidhya N, et al : Hyperbilirubinemia after cardiac surgery : An observational study. Asian Cardiovasc Thorac Ann 2015 ; 23 : 1039-1043
 
50) Nishi H, Sakaguchi T, Miyagawa S, et al : Frequency, risk factors and prognosis of postoperative hyperbilirubinemia after heart valve surgery. Cardiology 2012 ; 122 : 12-19
 
51) Hosotsubo KK, Nishimura M, Nishimura S : Hyperbilirubinemia after major thoracic surgery : comparison between open-heart surgery and oesophagectomy. Crit Care 2000 ; 4 : 180-187
 
52) 古川博史, 山根尚貴, 田村太志, ほか : 開心術後の難治性高ビリルビン血症に対する漢方薬茵陳蒿湯の使用. 胸部外科 2019 ; 72 : 1049-1052
 
P.143 掲載の参考文献
1) Yasunaga H : Effect of Japanese Herbal Kampo Medicine Goreisan on Reoperation Rates after Burr-Hole Surgery for Chronic Subdural Hematoma : Analysis of a National Inpatient Database. Evid Based Complement Alternat Med 2015 ; 2015 : 817616
PubMed
2) Iwasaki K, Kato S, Monma Y, et al : A pilot study of banxia houpu tang, a traditional Chinese medicine, for reducing pneumonia risk in older adults with dementia. J Am Geriatr Soc 2007 ; 55 : 2035-2040
 
P.148 掲載の参考文献
1) Chong BH : Heparin-induced thrombocytopenia. Aust N Z J Med 1992 ; 22 : 145-152
 
2) Walls JT, Curtis JJ, Silver D, Boley TM : Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery 1990 ; 108 : 686-692
 
3) Spencer FA : Heparin-induced thrombocytopenia : Patient profiles and clinical manifestations. J Thromb Thrombolysis 2000 ; 10 : 21-25
 
4) Baker KM, Flattery MP : Heparin-induced thrombocytopenia cardiovascular patients : recognition and treatment. Prog Cardiovasc Nurs 2006 ; 21 : 47-50
 
5) 松尾武文 : ヘパリン起因性血小板減少症 (Heparin-induced thrombocytopenia : HIT) の診断. 日血栓止血会誌 2008 ; 19 : 191-194
 
6) Carrier M, Robitaille D, Perrault LP, et al : Heparin versus danaparoid in off-pump coronary bypass grafting : result of prospective randomized clinical trial. J Thorac Cardiovasc Surg 2003 ; 125 : 325-329
 
7) Bott JN, Reddy K, Krick S : Bivalirudin use in off-pump myocardial revascularization in patients with heparininduced thrombocytopenia. Ann Thorac Surg 2003 ; 76 : 273-275
 
8) Ide H, Fujiki T, Sato M, et al : Off-pump coronary artery bypass for a heparin-allergic patient. Jpn J Thorac Cardiovasc Surg 2001 ; 49 : 250-254
 
9) Kieta DR, McCammon AT, Holman WL, Nielsen VG : Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth Analg 2003 ; 96 : 956-958
 
10) Ohno H, Higashidate M, Yokosuka T : Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery. Heart Vessel 2003 ; 18 : 40-42
 
11) 岡本彰祐, 池田康夫 : HIT診療の手引き. 神戸 : HIT情報センター ; 2004. p.12-18
 
P.149 掲載の参考文献
1) Vaitkus PT, Barnathan ES : Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction : a meta-analysis. J Am Coll Cardiol 1993 ; 22 : 1004-1009
 
2) Warkentin TE, Kelton JG : Temporal aspects of Heparin-induced thrombocytopenia. N Engl J Med 2001 ; 344 : 1286-1292
 
3) Potzsch B, Klovekorn WP, Madlener K : Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000 ; 343 : 515
PubMed
4) Koster A : Intraoperative anticoagulation in patients with HT. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia, Forth Edition. New York : Informa Healthcare ; 2007. p.495-497
 
5) Dhakal P, Giri S, Pathak R, Bhatt VR : Heparin Reexposure in Patients With a History of Heparin-Induced Thrombocytopenia. Clin Appl Thromb Hemost 2015 ; 21 : 626-631
 
P.154 掲載の参考文献
1) Picard F, Sayah N, Spagnoli V, et al : Vasospastic angina : A literature review of current evidence. Arch Cardiovasc Dis 2019 ; 112 : 44-55
 
2) Collison D, Copt S, Mizukami T, et al : Angina After Percutaneous Coronary Intervention : Patient and Procedural Predictors. Circ Cardiovasc Interv 2023 ; 16 : e012511
PubMed
3) Maron DJ, Hochman JS, Reynolds HR, et al : Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med 2020 ; 382 : 1395-1407
 
4) Puricel S, Kallinikou Z, Espinola J, et al : Comparison of endothelium-dependent and -independent vasomotor response after abluminal biodegradable polymer biolimus-eluting stent and persistent polymer everolimuseluting stent implantation (COMPARE-IT). Int J Cardiol 2016 ; 202 : 525-531
 
5) Hao K, Takahashi J, Kikuchi Y, et al : Prognostic Impacts of Comorbid Significant Coronary Stenosis and Coronary Artery Spasm in Patients With Stable Coronary Artery Disease. J Am Heart Assoc 2021 ; 10 : e017831
PubMed
6) 日本循環器学会/日本心血管インターベンション治療学会/日本心臓病学会 : 2023年JCS/CVIT/JCCガイドライン フォーカスアップデート版 冠攣縮性狭心症と冠微小循環障害の診断と治療. https://www.j-circ.or.jp/cms/wp-content/uploads/2023/03/JCS2023_hokimoto.pdf (cited 2023 Mar 10)
 
7) He GW : Arterial grafts for coronary surgery : vasospasm and patency rate. J Thorac Cardiovasc Surg 2001 ; 121 : 431-433
 
P.158 掲載の参考文献
1) Najib MQ, Lee HR, DeValeria PA, et al : Anterolateral papillary muscle rupture : an unusual complication of septic coronary embolism. Eur J Echocardiogr 2011 ; 12 : E10
PubMed
2) Nurkalem Z, Gorgulu S, Orhan AL, et al : Papillary muscle rupture secondary to infective endocarditis. Echocardiography 2008 ; 25 : 901-903
 
3) Badri M, Sardar MR, Khitri A, et al : Isolated posteromedial papillary muscle endocarditis. Eur Heart J Cardiovasc Imaging 2012 ; 13 : 630
PubMed
4) Maruo T, Komiya T, Shimamoto T, et al : Spontaneous papillary muscle rupture with localized endocarditis. Eur Heart J Cardiovasc Imaging 2015 ; 16 : 115
PubMed
5) 寺井浩, 岡田祐二, 浜谷秀宏, ほか : 感染性心内膜炎による乳頭筋完全断裂の1治験例. 日胸外会誌 1994 ; 7 : 1101-1104
 
6) Moorjani N, Saad R, Gallagher P, Livesey S : Endocarditis of the mitral valve posteromedial papillary muscle. J Card Surg 2014 ; 29 : 213-215
 
7) Whitehead NJ, Li S, Lai K : Anterolateral papillary rupture in Staphylococcus aureus endocarditis due to direct bacterial invasion of papillary muscle. Echocardiography 2017 ; 34 : 1382-1384
 
8) 日本循環器学会 : 感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/07/JCS2017_nakatani_h.pdf (cited 2021 Jun 01)
 

【研究会】

P.165 掲載の参考文献
1) Gyimesi G, Pujol Gimenez J, Kanai Y, Hediger MA : Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors : from molecular discovery to clinical application. Pflugers Arch 2020 ; 472 : 1177-1206
 
2) Bailey CJ : Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011 ; 32 : 63-71
 
3) Packer M : SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce as tate of fasting mimicry : a paradigm shift in understanding their mechanism of action. Diabetes Care 2020 ; 43 : 508-511
 
4) Hediger MA, Coady MJ, Ikeda TS, Wright EM : Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 1987 ; 330 : 379-381
 
5) Turk E, Zabel B, Mundlos S, et al : Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 1991 ; 350 : 354-356
 
6) Kanai Y, Lee WS, You G, et al : The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994 ; 93 : 397-404
 
7) You G, Lee WS, Barros EJ, et al : Molecular characteristics of Na+ -coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 1995 ; 270 : 29365-29371
 
8) van den Heuvel LP, Assink K, Willemsen M, Monnens L : Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002 ; 111 : 544-547
 
9) Vallon V, Platt KA, Cunard R, et al : SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011 ; 22 : 104-112
 
10) Coady MJ, El Tarazi A, Santer R, et al : MAP17 Is a Necessary Activator of Renal Na+/Glucose Cotransporter SGLT2. J Am Soc Nephrol 2017 ; 28 : 85-93
 
11) Niu Y, Liu R, Guan C, et al : Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter. Nature 2022 ; 601 : 280-284
 
12) Rossetti L, Shulman GI, Zawalich W, DeFronzo RA : Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987 ; 80 : 1037-1044
 
13) Rossetti L, Smith D, Shulman GI, et al : Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987 ; 79 : 1510-1515
 
14) Cefalu WT : Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest 2014 ; 124 : 485-487
 
15) Liu JJ, Lee T, DeFronzo RA : Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012 ; 61 : 2199-2204
 
16) Chen J, Williams S, Ho S, et al : Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010 ; 1 : 57-92
 
17) Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F : SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 2009 ; 84 : 111-118
 
18) Ohgaki R, Wei L, Yamada K, et al : Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther 2016 ; 358 : 94-102
 
19) Mori K, Saito R, Nakamaru Y, et al : Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. Biopharm Drug Dispos 2016 ; 37 : 491-506
 
20) Uthman L, Baartscheer A, Bleijlevens B, et al : Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts : inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 2018 ; 61 : 722-726
 
21) Griffin M, Rao VS, Ivey-Miranda J, et al : Empagliflozin in Heart Failure : Diuretic and Cardiorenal Effects. Circulation 2020 ; 142 : 1028-1039
 
22) Zinman B, Wanner C, Lachin JM, et al ; EMPA-REG OUTCOME Investigators : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015 ; 373 : 2117-2128
 
23) Mazer CD, Hare GMT, Connelly PW, et al : Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation 2020 ; 141 : 704-707
 
P.173 掲載の参考文献
1) Yasui A, Lee G, Hirase T, et al : Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes. Diabetes Ther 2018 ; 9 : 863-871
 
2) Nassif ME, Qintar M, Windsor SL, et al : Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure : Results From the EMBRACE-HF Trial. Circulation 2021 ; 143 : 1673-1686
 
3) Fitchett D, Inzucchi SE, Zinman B, et al : Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Heart Fail 2021 ; 8 : 4517-4527
 
4) Nakashima M, Miyoshi T, Ejiri K, et al : Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction. ESC Heart Fail 2022 ; 9 : 712-720
 
5) Hallow KM, Helmlinger G, Greasley PJ, et al : Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 2018 ; 20 : 479-487
 
6) Patoulias D, Katsimardou A, Fragakis N, et al : Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus : a meta-analysis of randomized controlled trials. Acta Diabetol 2023 ; 60 : 1-8
 
7) Ferrannini E, Baldi S, Frascerra S, et al : Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes 2016 ; 65 : 1190-1195
 
8) Selvaraj S, Fu Z, Jones P, et al : Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction : DEFINE-HF. Circulation 2022 ; 146 : 808-818
 
9) Hundertmark MJ, Adler A, Antoniades C, et al : Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin : The Randomized, Controlled EMPA-VISION Trial. Circulation 2023 ; 147 : 1654-1669
 
10) Hahn VS, Petucci C, Kim MS, et al : Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction. Circulation 2023 ; 147 : 1147-1161
 
11) Zannad F, Ferreira JP, Butler J, et al : Effect of empagliflozin on circulating proteomics in heart failure : mechanistic insights into the EMPEROR programme. Eur Heart J 2022 ; 43 : 4991-5002
 
12) Wanner C, Inzucchi SE, Lachin JM, et al : Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016 ; 375 : 323-334
 
13) Anker SD, Butler J, Filippatos G, et al : Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021 ; 385 : 1451-1461
 
14) Perkovic V, Jardine MJ, Neal B, et al : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019 ; 380 : 2295-2306
 
15) Keidai Y, Yoshiji S, Hasebe M, et al : Stabilization of kidney function and reduction in heart failure events with sodium-glucose co-transporter 2 inhibitors : A meta-analysis and meta-regression analysis. Diabetes Obes Metab 2023 ; 25 : 2505-2513
 
16) Tomita I, Kume S, Sugahara S, et al : SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. Cell Metab 2020 ; 32 : 404-419.e6
 
17) Fuchs Andersen C, Omar M, Glenthoj A, et al : Effects of empagliflozin on erythropoiesis in heart failure : data from the Empire HF trial. Eur J Heart Fail 2023 ; 25 : 226-234
 
18) Docherty KF, Welsh P, Verma S, et al : Iron Deficiency in Heart Failure and Effect of Dapagliflozin : Findings From DAPA-HF. Circulation 2022 ; 146 : 980-994
 
19) Ndumele CE, Neeland IJ, Tuttle KR, et al : A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome : A Scientific Statement From the American Heart Association. Cirulation 2023 ; 148 : 1636-1664
 
P.181 掲載の参考文献
1) Buglioni A Burnett JC Jr : New Pharmacological Strategies to Increase cGMP. Annu Rev Med 2016 ; 67 : 229-243
 
2) Numata G, Takimoto E : Cyclic GMP and PKG Signaling in Heart Failure. Front Pharmacol 2022 ; 13 : 792798
PubMed
3) Nakagawa H, Saito Y : Roles of Natriuretic Peptides and the Significance of N eprilysin in Cardiovascular Diseases. Biology (Basel) 2022 ; 11 : 1017
 
4) Nakamura T, Tsujita K : Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG. J Cardiol 2021 ; 78 : 261-268
 
5) Kamel R, Leroy J, Vandecasteele G, Fischmeister R : Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure. Nat Rev Cardiol 2023 ; 20 : 90-108
 
6) McMurray JJ, Packer M, Desai AS, et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014 ; 371 : 993-1004
 
7) Greene SJ, Bauersachs J, Brugts JJ, et al : Management of Worsening Heart Failure With Reduced Ejection Fraction : JACC Focus Seminar 3/3. J Am Coll Cardiol 2023 ; 82 : 559-571
 
8) Lee DI, Zhu G, Sasaki T, et al : Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 2015 ; 519 : 472-476
 
9) Kokkonen-Simon KM, Saberi A, Nakamura T, et al : Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease. JCI Insight 2018 ; 3 : e121739
PubMed
10) Michel K, Herwig M, Werner F, et al : C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness. JCI Insight 2020 ; 5 : e139910
 
11) Werner F, Prentki Santos E, Michel K, et al : Ablation of C-type natriuretic peptide/cGMP signaling in fibroblasts exacerbates adverse cardiac remodeling in mice. JCI Insight 2023 ; 8 : e160416
PubMed
12) Sasaki H, Nagayama T, Blanton RM, et al : PDE5 inhibitor efficacy is estrogen dependent in female heart disease. J Clin Invest 2014 ; 124 : 2464-2471
 
13) Mishra S, Sadagopan N, Dunkerly-Eyring B, et al : Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice. J Clin Invest 2021 ; 131 : e148798
 
14) Solomon SD, Vaduganathan M, Claggett BL, et al : Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation 2020 ; 141 : 352-361
 
15) Armstrong PW, Lam CSP, Anstrom KJ, et al : Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction : The VITALITY-HFpEF Randomized Clinical Trial. JAMA 2020 ; 324 : 1512-1521
 
16) Kolijn D, Kovacs A, Herwig M, et al : Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator. Front Physiol 2020 ; 11 : 345
PubMed
17) Kolijn D, Pabel S, Tian Y, et al : Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovasc Res 2021 ; 117 : 495-507
 
P.190 掲載の参考文献
1) Hoit BD : Left atrial size and function : role in prognosis. J Am Coll Cardiol 2014 ; 63 (6) : 493-505
 
2) Kowallick JT, Kutty S, Edelmann F, et al : Quantification of left atrial strain and strain rate using Cardiovascular Magnetic Resonance myocardial feature tracking : a feasibility study. J Cardiovasc Magn Reson 2014 ; 16 (1) : 60
PubMed
3) Wilber DJ : Neurohormonal Regulation and the Left Atrial Appendage : Still More to Learn. J Am Coll Cardiol 2018 ; 71 (2) : 145-147
 
4) Freed BH, Daruwalla V, Cheng JY, et al : Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction. Circ Cardiovasc Imaging 2016 ; 9 (3) : 10.1161/CIRCIMAGING.115.003754 e003754.
 
5) Reddy YNV, Obokata M, Verbrugge FH, et al : Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. J Am Coll Cardiol 2020 ; 76 (9) : 1051-1064
 
6) Patel RB, Lam CSP, Svedlund S, et al : Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMISHFpEF study. Sci Rep 2021 ; 11 (1) : 4885
PubMed
7) Shah SJ, Lam CSP, Svedlund S, et al : Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction : PROMIS-HFpEF. Eur Heart J 2018 ; 39 (37) : 3439-3450
 
8) Kaye DM, Nanayakkara S, Vizi D, et al : Effects of Milrinone on Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 2016 ; 67 (21) : 2554-2556
 
9) Voors AA, Tamby JF, Cleland JG, et al : Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction : experimental data and clinical results from a phase 2a trial. Eur J Heart Fail 2020 ; 22 (9) : 1649-1658
 
10) Juni RP, Kuster DWD, Goebel M, et al : Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin. JACC Basic Transl Sci 2019 ; 4 (5) : 575-591
 
11) Bilal AS, Blackwood EA, Thuerauf DJ, Glembotski CC : Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation. Circulation 2021 ; 143 (20) : 2025-2027
 
12) Litwin SE, Komtebedde J, Hu M, et al : Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 2023 ; 11 (8 Pt 2) : 1103-1117
 
13) Litwin SE, Borlaug BA, Komtebedde J, Shah SJ : Update on Atrial Shunt Therapy for Treatment of Heart Failure. Struct Heart 2022 ; 6 (6) : 100090
PubMed
14) Feldman T, Mauri L, Kahwash R, et al : Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]) : A Phase 2, Randomized, Sham-Controlled Trial. Circulation 2018 ; 137 (4) : 364-375
 
15) Shah SJ, Borlaug BA, Chung ES, et al : Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II) : a randomised, multicentre, blinded, sham-controlled trial. Lancet 2022 ; 399 (10330) : 1130-1140
 
16) Borlaug BA, Blair J, Bergmann MW, et al : Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. Circulation 2022 ; 145 (21) : 1592-1604
 
P.200 掲載の参考文献
1) Taqueti VR, Di Carli MF : Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options : JACC State of the Art Review. J Am Coll Cardial 2018 ; 72 (21) : 2625-2641
 
2) Hokimoto S, Kaikita K, Yasuda S, et al : JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction. Circ J 2023 ; 87 (6) : 879-936
 
3) Kaski JC, Crea F, Gersh BJ, Camici PG : Reappraisal of Ischemic Heart Disease. Circulation 2018 ; 138 (14) : 1463-1480
 
4) Crea F, Montone RA, Rinaldi R : Pathophysiology of Coronary Microvascular Dysfunction. Circ J 2022 ; 86 (9) : 1319-1328
 
5) Takashio S, Yamamuro M, Izumiya Y, et al : Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. J Am Coll Cardiol 2013 ; 62 (7) : 632-640
 
6) Yuki H, Utsunomiya D, Izumiya Y, et al : Improvement in Microvascular Ischemia After Enzyme Replacement Therapy in Anderson-Fabry Disease-Computed Tomography Myocardial Perfusion Imaging. Circ J 2017 ; 81 (2) : 243-244
 
7) Tsujita K, Yamanaga K, Komura N, et al : Impact of left ventricular hypertrophy on impaired coronary microvascular dysfunction. Int J Cardiol 2015 ; 187 : 411-413
 
8) Paulus WJ, Tschope C : A novel paradigm for heart failure with preserved ejection fraction : comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013 ; 62 (4) : 263-271
 
9) Taqueti VR, Solomon SD, Shah AM, et al : Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018 ; 39 (10) : 840-849
 
10) Rush CJ, Berry C, Oldroyd KG, et al : Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 2021 ; 6 (10) : 1130-1143
 
11) Sugiyama S, Jinnouchi H, Kurinami N, et al : The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus. Intern Med 2018 ; 57 (15) : 2147-2156
 
12) Matsuzawa Y, Sugiyama S, Sugamura K, et al : Successful diet and exercise therapy as evaluated on self-assessment score significantly improves endothelial function in metabolic syndrome patients. Circ J 2013 ; 77 (11) : 2807-2815
 
P.211 掲載の参考文献
1) Gorter TM, Hoendermis ES, van Veldhuisen DJ, et al : Right ventricular dysfunction in heart failure with preserved ejection fraction : a systematic review and meta-analysis. Eur J Heart Fail 2016 ; 18 : 1472-1487
 
2) Gorter TM, van Veldhuisen DJ, Bauersachs J, et al : Right heart dysfunction and failure in heart failure with preserved ejection fraction : mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018 ; 20 : 16-37
 
3) Vonk Noordegraaf A, Westerhof BE, Westerhof N : The Relationship Between the Right Ventricle and its Load in Pulmonary Hypertension. J Am Coll Cardiol 2017 ; 69 : 236-243
 
4) Sera F, Ohtani T, Tamaki S, et al : Pulmonary hypertension with a precapillary component in heart failure with preserved ejection fraction. Heart 2023 ; 109 : 626-633
 
5) He Q, Lin Y, Zhu Y, et al : Clinical Usefulness of Right Ventricle-Pulmonary Artery Coupling in Cardiovascular Disease. J Clin Med 2023 ; 12 : 2526
 
6) Guazzi M, Dixon D, Labate V, et al : RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction : Stratification of Clinical Phenotypes and Outcomes. JACC Cardiovasc Imaging 2017 ; 10 : 1211-1221
 
7) Guazzi M, Bandera F, Pelissero G, et al : Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure : an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol 2013 ; 305 : H1373-1381
 
8) Bosch L, Lam CSP, Gong L, et al : Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. Eur J Heart Fail 2017 ; 19 : 1664-1671
 
9) Nakagawa A, Yasumura Y, Yoshida C, et al : Prognostic Importance of Right Ventricular-Vascular Uncoupling in Acute Decompensated Heart Failure With Preserved Ejection Fraction. Circ Cardiovasc Imaging 2020 ; 13 : e011430
PubMed
10) Vachiery JL, Delcroix M, Al-Hiti H, et al : Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018 ; 51 : 1701886
 
11) Hoendermis ES, Liu LC, Hummel YM, et al : Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension : a randomized controlled trial. Eur Heart J 2015 ; 36 : 2565-2573
 
12) Burkhoff D, Borlaug BA, Shah SJ, et al : Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF : Results of the Randomized Placebo-Controlled HELP Trial. JACC Heart Fail 2021 ; 9 : 360-370
 
13) Nanayakkara S, Byrne M, Mak V, et al : Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc 2020 ; 9 : e015026
PubMed
P.220 掲載の参考文献
1) Cohen JB, Schrauben SJ, Zhao L, et al : Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction : Detailed Phenotypes, Prognosis, and Response to Spironolactone. JACC Heart Fail 2020 ; 8 : 172-184
 
2) Kinugasa Y, Yamamoto K : The challenge of frailty and sarcopenia in heart failure with preserved ejection fraction. Heart 2017 ; 103 : 184-189
 
3) 衣笠良治 : HFpEFのフレイルにどう介入するか? 医学のあゆみ. 2023 ; 285 : 1073-1077
 
4) Kitzman DW, Whellan DJ, Duncan P, et al : Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. N Engl J Med 2021 ; 385 : 203-216
 
5) Miyagi M, Kinugasa Y, Sota T, et al : Diaphragm Muscle Dysfunction in Patients With Heart Failure. J Card Fail 2018 ; 24 : 209-216
 
6) Kinugasa Y, Miyagi M, Sota T, et al : Dynapenia and diaphragm muscle dysfunction in patients with heart failure. Eur J Prev Cardiol 2018 ; 25 : 1785-1786
 
7) Kinugasa Y, Sota T, Ishiga N, et al : Home-based Inspiratory Muscle Training in Patients With Heart Failure and Preserved Ejection Fraction : A Preliminary Study. J Card Fail 2020 ; 26 : 1022-1023
 
8) Hersberger L, Dietz A, Burgler H, et al : Individualized Nutritional Support for Hospitalized Patients With Chronic Heart Failure. J Am Coll Cardiol 2021 ; 77 : 2307-2319
 
9) Kinugasa Y, Sugihara S, Yamada K, et al : Carnitine insufficincy is associated with adverse outcomes in patients with heart failure with preserved ejection fraction. J Aging Res Clin Practice 2016 ; 5 : 187-193
 
10) Kinugasa Y, Sota T, Ishiga N, et al : l-Carnitine supplementation in heart failure patients with preserved ejection fraction ; a pilot study. Geriatr Gerontol Int 2020 ; 20 : 1244-1245
 
11) Kinugasa Y, Nakamura K, Kamitani H, et al : Trimethylamine N-oxide and outcomes in patients hospitalized with acute heart failure and preserved ejection fraction. ESC Heart Fail 2021 ; 8 (3) : 2103-2110
 
12) Koeth RA, Wang Z, Levison BS, et al : Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013 ; 19 : 576-585
 

書評

最近チェックした商品履歴

Loading...